GSK plc
Bear Case (25th pct.)
76.7% vs price
Base Case (Median)
122.9% vs price
Bull Case (75th pct.)
142.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $115.87 | 122.9% | High (40%) |
| PE Comparable | $81.04 | 55.9% | Medium (25%) |
| Growth Trajectory DCF | $123.31 | 137.2% | Medium (20%) |
| Graham Number | $36.36 | -30.0% | Medium (40%) |
| EV/EBITDA | $102.71 | 97.6% | Medium (20%) |
| EV/FCF | $145.59 | 180.1% | Medium (20%) |
| Earnings Power Value | $129.02 | 148.2% | Medium (50%) |
Based on 7 out of 8 methods, GSK appears undervalued at the current price of $51.98. The base case fair value of $115.87 implies 122.9% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.